Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story
On August 11, Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results that on the surface look almost too good to be true. Non-GAAP diluted EPS jumped 40% year over year to $2.91, and full-year adjusted free cash flow hit $5 billion. But a large piece of that quarterly jump came from a one-time tariff refund, and the company’s own guidance for the year ahead points to a much more normal pace of growth. That gap between the headline number and what’s actually repeatable is where this story gets interesting.
Cardinal Health’s (CAH) Big Earnings Beat Hides A More Complicated Story
Bull Case: A Portfolio Firing Together
Cardinal Health’s fiscal 2026 was broad, not lucky. Operational growth was broad-based across segments, with fourth-quarter total revenue reaching $63.7 billion (up 6% year over year) driven by solid demand in Pharmaceutical and Specialty Solutions. Non-GAAP earnings per share have more than doubled since fiscal 2022, from $5.07 to $11.26, and adjusted free cash flow grew from $2.3 billion to $5 billion over that same four-year stretch, funding $7 billion returned to shareholders.
Pharmaceutical and Specialty Solutions did the heavy lifting again in the fourth quarter, with revenue up 6% to $58.8 billion and segment profit up 21% to $645 million on strength in both brand and Specialty. BioPharma Solutions landed two additional gene therapy 3PL commercialization agreements, with Cardinal Health now exclusively servicing nearly half the cell and gene therapy market and supporting approximately three-fourths of the total market overall. The smaller growth businesses continue to compound rapidly: Nuclear PET and Theranostics revenue grew 20% and 30% respectively in the fourth quarter, while at-Home Solutions posted a 99% total fill rate with its best quarter ever for on-time departures. The board also just authorized a $5 billion increase to the buyback program, pushing total authorization to $6.4 billion, and locked in a long-term Kroger contract extension along with a renewal of its largest medical products customer.
Bear Case: Where The Growth Gets Murky
Look closer at that 40% EPS jump, though, and a chunk of it isn’t repeatable. About $0.31 of the $2.91 in quarterly diluted earnings per share, roughly 15 percentage points of the 40% growth, came from a one-time $100 million net benefit tied to IEEPA tariff refunds landing in the Global Medical Products and Distribution segment. Strip that out and GMPD’s fourth-quarter profit was just $50 million, and the company says it continues to incur ongoing costs from the tariffs that replaced IEEPA. Reported GMPD revenue actually fell 2% for the quarter.
Guidance for fiscal 2027 reflects that same moderation. Pharma segment revenue is guided to grow just 3% to 5%, as management expects demand to normalize and as 2027 IRA drug pricing changes annualize into the numbers. GMPD’s first quarter of fiscal 2027 is expected to come in at roughly half of last year’s first quarter due to currency effects and distributor purchase timing. Cardinal Health also flagged that if conflicts in Iran drag on, GMPD’s profit could land at the low end of its guided range, and that rising fuel and commodity costs are expected to offset the tariff tailwind the company is otherwise counting on. Fourth quarter SG&A also grew 9.5%, partly from acquisition integration costs.
What The Market Is Pricing In
Hedge fund ownership in Cardinal Health rose from 60 funds to 66 quarter over quarter, a sign of building institutional conviction rather than retreat. Short interest sits at just 3.27% of float, which suggests little organized skepticism is betting against the stock right now. The stock trades at a forward price-to-earnings ratio of 19.16, as of August 19, a multiple that assumes steady execution rather than explosive growth. That combination suggests the market has largely priced in Cardinal Health’s operational turnaround already.
The Real Test Starts Now
Cardinal Health heads into fiscal 2027 with a stronger balance sheet, an expanded buyback authorization, and momentum across Specialty and its smaller growth businesses that isn’t fading. But the fourth quarter also showed how much of the headline number depended on a refund that won’t repeat, and management’s own guidance calls for meaningfully slower Pharma revenue growth than the year just finished. Specialty, Theranostics, and at-Home Solutions would need to keep compounding fast enough to offset that slower Pharma pace and justify the optimism embedded in the stock’s current multiple. GMPD, meanwhile, still has to show it can generate profit without a one-time refund propping it up, with the Iran-related risk hanging over that segment’s outlook.
While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
For decades, Berkshire Hathaway’s quarterly stock filings have been treated like a roadmap into Warren Buffett’s thinking. However, the latest one feels very special. Berkshire […]
